JP2022532490A5 - - Google Patents

Info

Publication number
JP2022532490A5
JP2022532490A5 JP2021563296A JP2021563296A JP2022532490A5 JP 2022532490 A5 JP2022532490 A5 JP 2022532490A5 JP 2021563296 A JP2021563296 A JP 2021563296A JP 2021563296 A JP2021563296 A JP 2021563296A JP 2022532490 A5 JP2022532490 A5 JP 2022532490A5
Authority
JP
Japan
Prior art keywords
antibody
seq
amino acid
acid sequence
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021563296A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022532490A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/032515 external-priority patent/WO2020232019A1/en
Publication of JP2022532490A publication Critical patent/JP2022532490A/ja
Priority to JP2025015378A priority Critical patent/JP2025065211A/ja
Publication of JP2022532490A5 publication Critical patent/JP2022532490A5/ja
Pending legal-status Critical Current

Links

JP2021563296A 2019-05-13 2020-05-12 癌の治療における有効性の増強のためのpd-1阻害剤とlag-3阻害剤の組み合わせ Pending JP2022532490A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025015378A JP2025065211A (ja) 2019-05-13 2025-01-31 癌の治療における有効性の増強のためのpd-1阻害剤とlag-3阻害剤の組み合わせ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962847068P 2019-05-13 2019-05-13
US62/847,068 2019-05-13
PCT/US2020/032515 WO2020232019A1 (en) 2019-05-13 2020-05-12 Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025015378A Division JP2025065211A (ja) 2019-05-13 2025-01-31 癌の治療における有効性の増強のためのpd-1阻害剤とlag-3阻害剤の組み合わせ

Publications (2)

Publication Number Publication Date
JP2022532490A JP2022532490A (ja) 2022-07-15
JP2022532490A5 true JP2022532490A5 (cg-RX-API-DMAC7.html) 2025-03-31

Family

ID=71069936

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021563296A Pending JP2022532490A (ja) 2019-05-13 2020-05-12 癌の治療における有効性の増強のためのpd-1阻害剤とlag-3阻害剤の組み合わせ
JP2025015378A Pending JP2025065211A (ja) 2019-05-13 2025-01-31 癌の治療における有効性の増強のためのpd-1阻害剤とlag-3阻害剤の組み合わせ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025015378A Pending JP2025065211A (ja) 2019-05-13 2025-01-31 癌の治療における有効性の増強のためのpd-1阻害剤とlag-3阻害剤の組み合わせ

Country Status (17)

Country Link
US (1) US20220249659A1 (cg-RX-API-DMAC7.html)
EP (1) EP3969040A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022532490A (cg-RX-API-DMAC7.html)
KR (1) KR20220007593A (cg-RX-API-DMAC7.html)
CN (2) CN113825527A (cg-RX-API-DMAC7.html)
AU (1) AU2020276242B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021021713A2 (cg-RX-API-DMAC7.html)
CA (1) CA3136568A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002966A1 (cg-RX-API-DMAC7.html)
EA (1) EA202192528A1 (cg-RX-API-DMAC7.html)
IL (1) IL287728A (cg-RX-API-DMAC7.html)
MA (1) MA55965A (cg-RX-API-DMAC7.html)
MX (1) MX2021013815A (cg-RX-API-DMAC7.html)
PH (1) PH12021552675A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202111262XA (cg-RX-API-DMAC7.html)
WO (1) WO2020232019A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202107760B (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI756187B (zh) * 2015-10-09 2022-03-01 美商再生元醫藥公司 抗lag3抗體及其用途
US20210128710A1 (en) * 2019-11-04 2021-05-06 Inovio Pharmaceuticals, Inc. Combination therapy to treat brain cancer
US20250270321A1 (en) * 2021-02-23 2025-08-28 Regeneron Pharmaceuticals, Inc. Methods of treating lung cancer by administering a pd-1 inhibitor
IL309120A (en) * 2021-07-28 2024-02-01 Hoffmann La Roche Methods and compositions for the treatment of cancer
WO2023019240A2 (en) 2021-08-13 2023-02-16 Inovio Pharmaceuticals Inc. Combination therapy to treat brain cancer
CN115887669A (zh) * 2022-12-19 2023-04-04 国纳之星(上海)纳米科技发展有限公司 一种治疗癌症的药物组合物
CN115869399B (zh) * 2022-12-28 2024-01-12 广州誉衡生物科技有限公司 一种药物组合物和药物制剂及其在治疗非小细胞肺癌中的应用
CN115845052B (zh) * 2022-12-28 2023-12-29 广州誉衡生物科技有限公司 一种药物组合物和药物制剂及其在治疗结肠癌中的应用
CN121127264A (zh) * 2023-03-13 2025-12-12 瑞泽恩制药公司 用于在治疗黑素瘤中增强疗效的pd-1抑制剂和lag-3抑制剂组合
CN122180519A (zh) * 2023-11-15 2026-06-09 瑞泽恩制药公司 用于增强在治疗肺癌中的功效的pd-1抑制剂和lag-3抑制剂的组合
AU2024391585A1 (en) * 2023-11-30 2026-06-04 Regeneron Pharmaceuticals, Inc. Methods of treating cancer by administering a combination therapy including a neoadjuvant pd-1 inhibitor
CN119607196A (zh) * 2023-12-13 2025-03-14 正大天晴药业集团股份有限公司 抗lag-3抗体与抗pd-1抗体的应用
WO2025237275A1 (zh) * 2024-05-13 2025-11-20 南京维立志博生物科技股份有限公司 用于治疗肿瘤的抗lag-3抗体或其抗原结合部分

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5976877A (en) 1990-01-08 1999-11-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses
FR2656800B1 (fr) 1990-01-08 1992-05-15 Roussy Inst Gustave Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
JP3700859B2 (ja) 1994-05-06 2005-09-28 アンスティテュ ギュスタブ ルシ Lag−3タンパク質の可溶性ポリペプチドフラクション;製造方法、治療用製剤、抗イディオタイプ抗体
US5532210A (en) 1994-06-08 1996-07-02 E. I. Du Pont De Nemours And Company High temperature superconductor dielectric slow wave structures for accelerators and traveling wave tubes
PT843557E (pt) 1995-07-21 2003-03-31 Applied Research Systems Metodos para detectar indentificar isolar e etiquetar e abordar selectivamente linfocitos th1 por intermedio da proteina lag-3
EP0900841A1 (en) 1997-06-18 1999-03-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) LAG-3 splice variants
WO2000032634A1 (en) 1998-12-01 2000-06-08 Protein Design Labs, Inc. Humanized antibodies to gamma-interferon
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
ES2539411T3 (es) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receptor para la B7-4 y su utilización
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
US20060240024A1 (en) 2003-02-28 2006-10-26 The Johns Hopkins University T cell regulation
EP1802193B1 (en) 2004-10-19 2014-04-30 Regeneron Pharmaceuticals, Inc. Method for generating a mouse homozygous for a genetic modification
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
US9244059B2 (en) 2007-04-30 2016-01-26 Immutep Parc Club Orsay Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
EA201500417A1 (ru) 2008-08-25 2015-11-30 Эмплиммьюн, Инк. Композиции антагонистов pd-1 и способы применения
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
US8686119B2 (en) 2011-07-24 2014-04-01 Curetech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
RS60538B1 (sr) 2013-03-15 2020-08-31 Glaxosmithkline Ip Dev Ltd Anti-lag-3 vezujući proteini
RS64268B1 (sr) * 2013-09-20 2023-07-31 Bristol Myers Squibb Co Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
EP3254110B1 (en) 2015-02-03 2020-03-18 Ventana Medical Systems, Inc. Histochemical assay for evaluating expression of programmed death ligand 1 (pd-l1)
WO2016191751A1 (en) 2015-05-28 2016-12-01 Bristol-Myers Squibb Company Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
RU2760582C2 (ru) 2015-09-02 2021-11-29 Иммутеп С.А.С. Анти-LAG-3 антитела
TWI756187B (zh) * 2015-10-09 2022-03-01 美商再生元醫藥公司 抗lag3抗體及其用途
TWI822521B (zh) * 2016-05-13 2023-11-11 美商再生元醫藥公司 藉由投予pd-1抑制劑治療皮膚癌之方法
EP3848393A1 (en) * 2016-05-18 2021-07-14 Boehringer Ingelheim International GmbH Antibody molecules for cancer treatment
KR20230133934A (ko) 2016-10-11 2023-09-19 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
US11390676B2 (en) 2016-10-13 2022-07-19 Symphogen A/S Anti-LAG-3 antibodies and compositions
RS67792B1 (sr) 2016-12-01 2026-03-31 Regeneron Pharma Radio-obeležena anti-pd-l1 antitela za imuno-pet snimanje
BR112019016336A2 (pt) 2017-02-10 2020-03-31 Regeneron Pharmaceuticals, Inc. Conjugado de anticorpo radiorrotulado, método para imageamento de um tecido que expressa lag3 e para tratar um tumor, e, composto.
AU2018247916B2 (en) * 2017-04-05 2025-04-24 Les Laboratoires Servier Combination therapies targeting PD-1, TIM-3, and LAG-3

Similar Documents

Publication Publication Date Title
JP2022050618A5 (cg-RX-API-DMAC7.html)
TWI786044B (zh) 藉由投予pd-1抑制劑治療皮膚癌之方法
JP7126941B2 (ja) がんを治療するための抗pd-1抗体と二重特異性抗cd20/抗cd3抗体の組合せ
AU2020276242B2 (en) Combination of PD-1 inhibitors and LAG-3 inhibitors for enhanced efficacy in treating cancer
JP2019515008A5 (cg-RX-API-DMAC7.html)
CN108602889A (zh) 医治急性成淋巴细胞性白血病的双特异性抗cd20/抗cd3抗体
IL321717A (en) Anti-PD-1 antibodies for the treatment of lung cancer
JP2021528423A5 (cg-RX-API-DMAC7.html)
JP2020508317A5 (cg-RX-API-DMAC7.html)
CA3129963A1 (en) Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer
TW202320827A (zh) 用於治療癌症之檢查點抑制劑和溶瘤病毒的組合
TWI899236B (zh) 通過投予pd-1抑制劑治療子宮頸癌的方法
NZ781933B2 (en) Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer
WO2025106736A2 (en) Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating lung cancer
RU2021128914A (ru) Ингибиторы пути il-4/il-13 для повышенной эффективности при лечении злокачественных новообразований
TH2001007178A (th) แอนติ-PD-1 แอนติบอดีและไบสเปซิฟิกแอนติ-CD3 x MUC16 แอนติบอดีสำหรับการผลิตตัวยาสำหรับการบำบัดหรือการยับยั้งการเจริญของเนื้องอกที่มีการแสดงออก MUC16
NZ748192B2 (en) Methods of treating skin cancer by administering a pd-1 inhibitor